RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC
No Thumbnail Available
Authors
Powles T.
Koshkin V.S.
Rosenberg J.E.
Matsubara N.
Brown J.R.
Drakaki A.
Campbell M.T.
Oliveira N.
Burgess E.
Iyer G.
Contact
Check for full-text access
Issue Date
2026
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
LBA631 Background: An estimated 60%-80% of patients (pts) with UC have HER2-expressing tumors. DV is an ADC comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. DV demonstrated promising antitumor activity and a manageable safety profile as monotherapy in Chinese pts with HER2-expressing (IHC 1+ or greater) la/mUC refractory to prior therapies. We report the primary analysis from Cohorts A and B of the global RC48G001 study assessing DV monotherapy in pts with HER2-expressing la/mUC (HER2-positive: IHC 3+, or IHC 2+/ISH-positive [Cohort A]; HER2-low: IHC 2+/ISH-negative, or IHC 1+ [Cohort B]) who progressed following systemic therapy. Method(s): RC48G001 (or C5731002) is a global, multicohort, single-arm, open-label, phase 2 study that enrolled pts with la/mUC who received 1-2 prior systemic therapies (incl. a platinum-containing regimen). HER2 expression was determined by central laboratory using the VENTANA HER2 IHC and HER2 Dual ISH DNA Probe Cocktail assays. Pts received 1.5 mg/kg DV monotherapy IV once per 2-week cycle. The primary endpoint (EP) was cORR per RECIST 1.1 by BICR. Secondary EPs included DOR, DCR, PFS (all per RECIST 1.1 by BICR), OS, and safety. A genAI tool (09/05/25; Pfizer; GPT-4o) assisted with the 1st draft; authors assume content responsibility. Result(s): At data cutoff (Sep 12, 2025), 73 pts were enrolled in Cohort A and 78 pts in Cohort B. 54.8% and 39.7% of pts had ECOG PS 0, and 68.5% and 82.1% had visceral disease in each cohort, respectively. Cohort A included 69.9% pts with IHC 3+ and 30.1% pts with IHC 2+/ISH-positive la/mUC. Cohort B included 28.2% pts with IHC 1+ and 69.2% pts with IHC 2+/ISH-negative la/mUC. Median follow-up was 11.3 months for Cohort A and 17.1 months for Cohort B. Pts received a median of 9 DV cycles in both cohorts. cORR per BICR was 54.9%, with a CR rate of 16.9%, in Cohort A, and 52.6%, with a CR rate of 18.4%, in Cohort B (Table). mPFS by BICR was 5.7 months in both cohorts. mOS was 20.0 months and 17.0 months in Cohort A and B, respectively. Grade >=3 TRAEs occurred in 62 (41.1%) pts, with fatigue (13.9%) being the most common. 16.6% of pts discontinued treatment (tx) due to AEs, most commonly peripheral sensory neuropathy (6.0%). Conclusion(s): This is the first presentation of DV monotherapy outcomes in a global population with HER2-expressing la/mUC. DV demonstrated promising antitumor activity and a manageable safety profile, consistent with results from China, supporting further evaluation. Clinical trial information: NCT04879329. [Table presented] Copyright © 2026 by American Society of Clinical Oncology
Description
Citation
Publisher
License
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume
Issue
2026 ASCO Genitourinary Cancers Symposium (February 26-28, 2026).